Q3 2026 Arrowhead Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Positive top-line Phase III results from SHASTA-3 and SHASTA-4 studies, with both meeting primary and all pre-specified secondary endpoints, showing median triglyceride reductions of 79% and 81%.
- Significant reduction in acute pancreatitis events, with a 78% reduction in the broad SHTG population and a 100% reduction in the highest-risk subgroup.
- Favorable safety and tolerability profile with no new safety signals, no clinically meaningful liver enzyme changes, no hypersensitivity, and no thrombocytopenia signal.
- Strong commercial momentum in the FCS launch, with prescriptions more than doubling quarter-over-quarter and over 400 unique prescribers.
- Expansion of regulatory approvals for Redemplo to five geographies, including the EU, Australia, Canada, China, and the U.S., with a unique label covering clinically diagnosed FCS patients in Europe.
- Acquisition of a priority review voucher to potentially accelerate FDA review of the SNDA for SHTG, potentially bringing the drug to market four months earlier.
- Robust pipeline progress, including positive interim data for ARO-INHBE in obesity/MASH, full enrollment of the Phase III Yosemite study for zodasiran, and upcoming data readouts for ARO-DiRPA and ARO-MAP-T.
- Strong balance sheet with approximately $1.6 billion in cash and investments, providing financial flexibility for ongoing development and commercialization.
- Partnership strategy yielding significant milestones, including a $25 million upfront payment from Madrigal for ARO-PNPLA-3, with potential for up to $975 million in milestones and royalties.
- Scalable commercial infrastructure designed to support future indications and multiple products, with plans to expand field force to address over 20,000 HCP targets for SHTG.
- Net loss widened to $194.3 million in the quarter, compared to $175.2 million in the prior year, driven by higher R&D and SG&A expenses.
- R&D expenses increased by $36 million year-over-year, reflecting continued high investment in clinical development and manufacturing.
- SG&A expenses rose to $47 million, up from $31 million, due to increased commercial headcount and launch support costs.
- The acquisition of the priority review voucher for $215 million represents a significant cash outlay, with the return dependent on successful approval and launch.
- Commercial revenue from Redemplo remains modest at approximately $2.4 million for the quarter, indicating early-stage launch revenue generation.
- The SHTG market launch is expected to be a slow ramp due to the need for extensive physician and patient education, potentially limiting near-term revenue growth.
- Uncertainty regarding ex-U.S. market revenue due to factors like MFN and varying reimbursement processes, which could impact international sales.
- The company is under embargo for detailed SHASTA-3/4 data until ESC, limiting transparency and potentially affecting investor confidence.
- The Phase III Yosemite study for zodasiran is not expected to complete until mid-2027, with data in the second half of 2027, delaying potential revenue from this program.
- The company faces competitive pressure in the SHTG market, with a competitor already launched, and the need to justify a premium price for Redemplo.
Welcome to the Arrowhead Pharmaceutical Conference Call. Throughout today's recorded presentation, all participants will be in a listen mode only.
After the presentation, there will be an opportunity to ask questions.
I will now hand the conference over to Vincent Anzaloni.
Senior Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Thank you, and good afternoon, everyone.
Thank you for joining us today to discuss Arrowhead's results for its fiscal 2026 third quarter ended June 30, 2026. With us today for management are President and CEO, Dr. Chris Anzaloni, who will provide an overview Andy Davis, Senior Vice President and Head of the Global Cardiometabolic Franchise, who will provide an update on commercialization activities Dr. James Hamilton, Chief Medical Officer and Head of R&D, who will discuss our development programs and Dan Appell, Chief Financial Officer, who will give a review of the financials. Following management
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
